Real-world effectiveness of trastuzumab deruxtecan in heavily pretreated her2-positive metastatic breast cancer: A single-center experience
Aim: Trastuzumab deruxtecan (T-DXd) has shown substantial activity in trials of HER2-positive metastatic breast cancer (mBC), but real-world data in heavily pretreated patients, in those with CNS metastases, and in patients started at reduced doses remain limited. To evaluate real-world efficacy and safety of T-DXd in...